View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 8, 2011updated 13 Jul 2022 11:14am

Abbott announces results of Humira trials

Abbott has announced the data from Premier and DE019 Phase III studies that investigated Humira (adalimumab) plus methotrexate for up to eight years in patients with early moderate to severe rheumatoid arthritis and up to ten years in patients with long-standing moderate to severe rheumatoid arthritis.

Abbott has announced the data from Premier and DE019 Phase III studies that investigated Humira (adalimumab) plus methotrexate for up to eight years in patients with early moderate to severe rheumatoid arthritis and up to ten years in patients with long-standing moderate to severe rheumatoid arthritis.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Humira, a TNF blocker used alone, with methotrexate, or with certain other medicines, helps to prevent further damage to bones and joints.

The randomised and controlled Premier trial involved methotrexate-naive patients with early moderate to severe rheumatoid arthritis, who received methotrexate, Humira or Humira plus methotrexate for two years of blinded treatment, and reported the radiographic, clinical and functional superiority of initial combination therapy over the individual monotherapies.

The randomised controlled DE019 trial enrolled patients with long-standing RA and demonstrated the clinical and radiographic superiority of Humira plus MTX over placebo plus MTX.

In both studies, patients were evaluated for disease activity, improvement in physical function and inhibition of radiographic progression and percentage of patients with no further radiographic progression.

University of California San Diego Division of Rheumatology Allergy and Immunology professor Arthur Kavanaugh said DE019 and Premier studies provide additional longer term data that support the ability of Humira to treat both early and long-standing moderate to severe rheumatoid arthritis.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena